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Background-—The incidence of type 1 diabetes mellitus (T1DM) in children is increasing, resulting in higher burden of
cardiovascular diseases due to diabetes mellitus–related vascular dysfunction.
Methods and Results-—We examined cardiovascular risk factors (CVRFs) and arterial parameters in 1809 youth with T1DM.
Demographics, anthropometrics, blood pressure, and laboratory data were collected at T1DM onset and 5 years later. Pulse wave
velocity and augmentation index were collected with tonometry. ANOVA or chi-square tests were used to test for differences in
measures of arterial parameters by CVRF. Area under the curve of CVRFs was entered in general linear models to explore
determinants of accelerate vascular aging. Participants at the time of arterial measurement were 17.64.5 years old, 50% female,
76% non-Hispanic white, and duration of T1DM was 7.81.9 years. Glycemic control was poor (glycated hemoglobin, 9.11.8%).
All arterial parameters were higher in participants with glycated hemoglobin ≥9% and pulse wave velocity was higher with lower
insulin sensitivity or longer duration of diabetes mellitus. Differences in arterial parameters were found by sex, age, and presence
of obesity, hypertension, or dyslipidemia. In multivariable models, higher glycated hemoglobin, lower insulin sensitivity, body mass
index, blood pressure, and lipid areas under the curve were associated with accelerated vascular aging.
Conclusions-—In young people with T1DM, persistent poor glycemic control and higher levels of traditional CVRFs are
independently associated with arterial aging. Improving glycemic control and interventions to lower CVRFs may prevent future
cardiovascular events in young individuals with T1DM. ( J Am Heart Assoc. 2019;8:e010150. DOI: 10.1161/JAHA.118.
010150.)
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D iabetes mellitus is one of the most common chronicdiseases in children,1,2 affecting nearly 1 of every 433
youth in the United States,3and the majority of diabetes
mellitus cases in childhood are due to type 1 diabetes mellitus
(T1DM).4 As the rate of T1DM continues to climb,3,5,6 this may
eventually result in higher cardiovascular diseases (CVD)
incidence, and CVD is one of the major causes of death in
adults with diabetes mellitus.7 One mechanism for the
increase in CVD may be diabetes mellitus–related abnormal-
ities in vascular structure and function that have been found
From the Heart Institute (E.M.U.), and Department of Endocrinology (L.M.D., A.S.S.), Cincinnati Children’s Hospital & University of Cincinnati, OH; Department of
Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC (S.I., R.D.); Department of Public Health, East Carolina University, Greenville, NC (R.A.B.);
Division of Pediatric Endocrinology & Diabetes, Medical University of South Carolina, Charleston, SC, USA (D.A.B., A.T.M.); Department of Pediatrics (S.R.D.), and
Barbara Davis Center for Childhood Diabetes (R.P.W.), University of Colorado School of Medicine, Aurora, CO; Division of Diabetes Translation, Centers for Disease
Control and Prevention, Atlanta, GA (G.I.); Northwest Lipid Metabolism and Diabetes Research Laboratory, University of Washington, Seattle, WA (S.M.M.); Department
of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, USA (A.T.M.); Department of Research & Evaluation, Kaiser Permanente Southern
California, Pasadena, CA (K.R.); Department of Epidemiology, Colorado School of Public Health, Aurora, CO (D.D.).
Accompanying Appendix S1, Tables S1 through S4 and Figure S1 are available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.118.010150
*A complete list of the SEARCH for Diabetes in Youth Study Group members can be found in Appendix S1.
Correspondence to: Elaine M. Urbina, MD, MS, Director, Preventive Cardiology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, MLC 7002,
Cincinnati, OH 45229. E-mail: elaine.urbina@cchmc.org
Received October 8, 2018; accepted January 16, 2019.
ª 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-
commercial and no modifications or adaptations are made.
DOI: 10.1161/JAHA.118.010150 Journal of the American Heart Association 1
ORIGINAL RESEARCH
D
ow
nloaded from
 http://ahajournals.org by on A
pril 2, 2020
in adolescents with diabetes mellitus.8–10 However, the true
prevalence of these abnormalities in youth with T1DM is not
known. It is also necessary to elucidate the correlates of
vascular dysfunction in young patients with T1DM, which may
guide future diabetes mellitus management recommenda-
tions. The presence of cardiac autonomic neuropathy (CAN)
has also been associated with higher arterial stiffness in both
adults and youth with diabetes mellitus, and it could be a
potential contributor to vascular aging. Furthermore, analyses
have examined the relationship between cardiovascular risk
factors (CVRFs) measured at one point in time and arterial
health in youth,11 but CVRF levels vary over time, and few
studies have examined the long-term burden of CVRFs on the
vasculature in youth with T1DM. Therefore, our aim was to
demonstrate that higher burden (area under the curve over
time) of CVRFs was associated with measures of arterial
stiffness and wave reflections in a cohort of individuals with
onset of T1DM before 20 years of age. We also sought to
determine if CAN was an independent predictor of arterial
parameters.
Methods
In accordance with the Transparency and Openness Promotion
Guidelines, the data that support the findings of this study are
available from the statistical coordinating center (Department
of Biostatistical Sciences, Wake Forest School of Medicine,
Winston-Salem, NC; sisom@wakehealth.edu; rdagosti@wake-
health.edu) upon reasonable request.
Description of the Study Population
Participants who were diagnosed with T1DM prior to 20 years
of age who participated in a population-based diabetes
mellitus registry at 5 US sites by the SEARCH for Diabetes
in Youth Study were eligible.2 Specifically, we recruited youth
with newly diagnosed T1DM in 2002 through 2006 or 2008,
who completed a SEARCH baseline examination for CVRFs
9 months after diagnosis and were reexamined at a follow
up visit at least 5 years after the baseline examination. The
average time from diagnosis to collection of arterial stiffness
measures was 7.91.9 years. Nearly 60% of participants had
one or more additional CVRF assessments between the
baseline and follow-up where vascular measures were
obtained. Diabetes mellitus type was defined at the baseline
visit using a classification developed by SEARCH12,13 on the
basis of ≥1 positive diabetes mellitus autoantibodies (see
below) and estimated insulin sensitivity score (IS, validated
equation including waist circumference, glycated hemoglobin
[HbA1c] and triglyceride levels).
12 T1DM was defined as the
presence of at least 1 positive antibody, regardless of insulin
sensitivity, or no positive antibodies and insulin sensitivity
(score ≥8.15). This study included participants with T1DM, as
defined above, with at least 1 measure of arterial stiffness,
and C-reactive protein levels ≤10 mg/Dl, as acute infection
may transiently affect arterial stiffness. The final analytic
sample consisted of 1809 participants. Institutional review
board approval was obtained at each site, and all participants
or their guardians gave informed consent.
CVRF Collection
All testing was performed under standardized conditions by
trained personnel. At baseline and at the follow-up visit,
participants were examined after an 8-hour overnight fast
while refraining from strenuous exercise, smoking, or any
caffeinated drinks. Short-acting insulin and oral medications
were withheld the morning of the visit until after the blood
draw and vascular studies were complete. Race/ethnicity was
self-reported using a 2000 US Census–based questionnaire
and was classified as non-Hispanic white, non-Hispanic black,
Hispanic, and Other. Height was measured in centimeters
using a stadiometer and weight in kilograms using a
standardized scale. Body mass index (BMI) was calculated
as weight in kilograms divided by the square of height in
meters, and age and sex-specific BMI z scores were derived
on the basis of the 2000 Centers for Disease Control and
Prevention national standards.14 Waist circumference was
measured using the National Health and Nutrition Examina-
tion Survey protocol and divided by height in centimeters to
calculate waist-to-height ratio.3 Resting systolic blood pres-
sure (SBP) and diastolic blood pressure were measured 3
times, using an aneroid sphygmomanometer and an
Clinical Perspective
What Is New?
• The relationship between longitudinal burden of cardiovas-
cular risk factors and objective measures of vascular health
in youth with type 1 diabetes mellitus (T1DM) has not been
previously explored.
• Poor glycemic control over time is a major determinant of
accelerated vascular aging in adolescents with T1DM.
• Traditional cardiovascular risk factors including obesity,
hypertension, and dyslipidemia also contribute to vascular
aging in youth with T1DM.
What Are the Clinical Implications?
• Tighter glycemic control needs to be achieved to reduce the
burden of micro- and macrovascular disease in young
people with T1DM.
• Individuals with T1DM should strive to increase the number
of ideal cardiovascular health metrics they are achieving as
adverse levels of traditional cardiovascular risk factors also
contribute to vascular aging in youth with T1DM.
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appropriate-sized cuff, after the participants were seated for
at least 5 minutes according to published guidelines.15 The
average of multiple measures of anthropometric and blood
pressure (BP) variables were used at each visit. Plasma
samples were analyzed for HbA1c, low-density lipoprotein
cholesterol, high-density lipoprotein (HDL) cholesterol, and
triglyceride levels at the study central laboratory (Northwest
Lipid Metabolism and Diabetes Research Laboratories,
University of Washington) as previously described.16 The
study central laboratory measured the diabetes mellitus
autoantibodies glutamic acid decarboxylase and insuloma-
associated-2 antibody,17 while zinc-T8 autoantibody was
analyzed at the Eisenbarth Laboratory (University of Colorado,
Aurora, CO).18
Arterial Parameters
At the follow-up visit, the average of 3 measurements of each
modality was obtained in a room with a stable temperature
after the participant rested for >10 minutes using previously
published protocols.10,19 Pulse wave velocity (PWV) was
collected using the SphygmoCor CPVH (AtCor Medical,
Sydney, Australia) from the carotid to the femoral artery
(PWVcf) representing central arterial stiffness in a large elastic
artery. Carotid to radial (PWVcr) and femoral to foot (PWVft)
were also obtained as measures of peripheral (muscular)
artery stiffness. Briefly, ECG-gated pressure wave data were
obtained with a tonometer placed on the artery. PWV is the
difference in proximal-to-distal artery path length (supraster-
nal notch to femoral artery measured directly with a caliper
minus suprasternal notch to carotid pulse measured with a
tape measure) divided by the difference in timing from the
peak of the ECG R-wave to foot of the proximal or distal
pressure wave. Augmentation index (AIx), a measure of wave
reflections influenced by vascular tone, heart rate, and cardiac
function, was collected with the same device. For AIx, the
pressure waves were calibrated by using mean arterial
pressure (MAP) and diastolic BP obtained in the same arm.
Using MAP instead of SBP is less prone to errors in calibration
attributable to pulse pressure amplification along the brachial
artery.20 A validated generalized transfer function was used to
calculate central aortic pressure and AIx (augmentation of
central pressure indexed to pulse pressure and adjusted to a
heart rate of 75 bpm). These techniques are highly repro-
ducible with coefficients of variability of 7% for PWV and
intraclass correlation coefficients of 0.7 to 0.9 for AIx.10 For
both PWV and AIx, a higher value indicates a stiffer vessel. To
define increased arterial stiffness, the 90th percentile for all
measures in healthy, lean adolescents and young adults of
similar age range, obtained via the same technique in our
laboratory, was used. The prevalence of increased stiffness
(≥90th percentile) was determined.
Assessment of CAN
At follow-up, presence of CAN was assessed by heart rate
variability testing using the SphygmoCor device (Atcor
Medical Inc, Sydney, Australia) as previously described.9 A
10-minute continuous ECG recording was obtained in the
supine position after a 5-minute rest. ECG tracings were
examined to ensure that R-waves were adequately identified
from artifacts and ectopic beats. The device analyzed time-
and frequency-domain parameters including SD of NN inter-
val, root mean square difference of the successive NN
interval, high-frequency power, low-frequency power, and low
frequency–to–high frequency ratio. The heart rate variability
test was considered abnormal if the values were below the
fifth percentile observed in age- and sex-matched healthy
controls (age 10–28 years, 54% females) from the SEARCH
CVD study.21 CAN was defined as presence of >3 abnormal
heart rate variability indices.
Statistical Analysis
In participants aged ≥18 years, normal or underweight was
defined as BMI<25 kg/m2, overweight as BMI 25 to
29.99 kg/m2, and obesity as BMI ≥30 kg/m2. In participants
aged <18 years, normal or underweight was defined as age-
and sex-specific BMI <85th percentile. Overweight was
defined as BMI at the 85th to 94th percentile, and obesity
was defined as a BMI ≥95th percentile.22 Hypertension was
defined as being on BP-lowering medication; BP ≥140/
90 mm Hg for young adults23; or ≥95th percentile for age,
sex, and height for adolescents.15 Dyslipidemia was defined
as being on lipid-lowering medication or low-density lipopro-
tein ≥130 mg/dL, HDL ≤40 mg/dL, triglycerides ≥150 mg/
dL, or non-HDL cholesterol ≥145 mg/dL.24 Smoking status
was obtained by self-report and categorized as never,
current, or former smoker as previously described.25 Physical
activity status was defined as participating in moderate or
vigorous activity for at least 20 minutes at least 3 or more
times per week. Sedentary behavior was defined as having
>2 hours/day of screen time regardless of physical activity
pattern.
The longitudinal cumulative exposure to CVRFs for each
participant was calculated as the weighted average of the
measures of interest during the participant’s time in the study
for waist-to-height ratio, SBP, and diastolic BP z scores, MAP,
and non-HDL cholesterol (potentially collected at baseline and
1-, 2-, and 5-year follow-up visits and weighted for the interval
between each measurement, similar to the area under the
curve [AUC]).
Statistical analyses were performed using SAS for Win-
dows (version 9.4; SAS Institute, Cary, NC), and P<0.05 was
considered significant. Mean (SD) or median (minimum,
maximum) as appropriate was used for continuous variables
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and counts (percentages) for categorical variables were
calculated for the entire study population. Participants were
categorized by demographics, duration of T1DM, and various
CVRFs at follow-up (presence of obesity, hypertension,
dyslipidemia, and lifestyle behaviors including smoking,
physical activity and sedentary behavior levels). ANOVA or
chi-square tests were used to test for differences in measures
of arterial stiffness and wave reflections in individuals with or
without an adverse CVRF. Bivariate correlations between
CVRFs, AUC for CVRFs, and arterial stiffness and wave
reflection measures were obtained to guide development of
multivariable general linear models (as all variables were
continuous) to explore factors associated with increased
arterial stiffness and wave reflections in the population.
Variables with a skewed distribution were log-transformed.
The first models constructed adjusted for age at diabetes
mellitus diagnosis, sex, race/ethnicity, clinic site, duration of
diabetes mellitus, and 1 CVRF at a time. CVRF interactions
with HbA1c AUC were also evaluated in the first series of
models. The final models included all covariates, and reduced
models retained only significant covariates.
Results
At the follow-up visit, the cohort (Table 1, N=1809) was
17.64.5 years old (range, 6–30) and 50% were female, 76%
non-Hispanic white, 10% non-Hispanic black, 12% Hispanic, and
2% Other. The mean duration of T1DM was 7.81.9 years
(range, 5–13). The mean BMI was 23.95.2 kg/m2, although
26% of the participants were overweight and 14% had obesity.
Mean BP was 106/6811/9 mm Hg within the normal range,
with 13% classified as having hypertension, including 6% on BP-
lowering medication. Mean lipid values were also within the
normal range, although 29% were categorized as having
dyslipidemia and 3% were on lipid-lowering medication.
Glycemic control was poor, with mean HbA1c 9.11.8% (range,
4–16). The mean daily dose of insulin was 0.9 (0.4 units/kg
body weight/day). While 68% of participants had never smoked
and 58% reported adequate levels of physical activity, 92%
reported high levels of sedentary behavior (data not shown).
Mean levels of arterial stiffness and wave reflections with
participants stratified by a single CVRF at follow-up are
displayed in Table 2. The prevalence of increased wave
reflections or arterial stiffness (value ≥90th percentile for
lean, healthy youth) was 7.0% for AIx, 19.4% for PWVcf, 13.0%
for PWVft, and 12.4% for PWVcr. All measures of arterial
stiffness and wave reflections were higher in individuals with
HbA1c ≥9% compared with those with better glycemic control
(P≤0.05, Figure). These remained significant after adjusting
for MAP, age, and sex for all measures except PWVcf
(Figure S1). All measures of PWV were higher in participants
with lower insulin sensitivity or longer duration of diabetes
mellitus. PWVcf and PWVft were significantly higher in people
classified as having CAN with a nonsignificant trend for
PWVcr. In analyses stratified by levels of other CVRFs,
differences in arterial parameters were found by sex (higher
AIx in females, higher PWVft and PWVcr in males) and race
(highest in non-Hispanic blacks for all measures). Higher
arterial parameters were also found for older individuals at
follow-up for all measures except wave reflections (AIx), which
Table 1. Description of the Study Population at Follow-Up
(N=1809)
Parameter
Mean (SD), Median
(min, max), or Percent
Age, y 17.6 (4.5)
Sex (% female) 49.5
Race/Ethnicity (%)
Non-Hispanic white 76.2
Non-Hispanic black 9.7
Hispanic 11.8
Other 2.4
Duration of T1DM, y 7.8 (1.9)
Height, m 1.7 (0.1)
Weight, kg 66.5 (19.6)
Waist-to-height ratio 0.5 (0.1)
Body mass index, kg/m2 23.9 (5.2)
Body mass index (z score) AUC 0.6 (0.9)
Systolic blood pressure, mm Hg 106.0 (11.0)
Systolic blood pressure (z score) AUC 0.4 (0.9)
Diastolic blood pressure, mm Hg 68.4 (8.9)
Diastolic blood pressure (z score) AUC 0.0 (1.1)
MAP (z score) AUC 78.3 (7.4)
Heart rate, bpm 69.5 (11.7)
Total cholesterol, mg/dL 169.7 (34.8)
LDL-cholesterol, mg/dL 96.2 (28.1)
Triglycerides, mg/dL 73.0 (17.0, 992.0)
HDL-cholesterol, mg/dL 55.2 (13.6)
HDL-cholesterol (mg/dL) AUC 56.0 (11.7)
Non–HDL-cholesterol, mg/dL 114.4 (34.7)
Non–HDL-cholesterol (mg/dL) AUC 109.4 (26.3)
Fasting glucose, mg/dL 212.8 (92.2)
Insulin dose (units/kg of body weight per day) 0.9 (0.4)
Glycated hemoglobin, % 9.1 (1.8)
Glycated hemoglobin (%) AUC 8.5 (1.3)
C-reactive protein, mg/dL 0.1 (0.0, 7.9)
AUC indicates area under the curve; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; MAP, mean arterial pressure; T1DM, type 1 diabetes mellitus.
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are lower with greater height with age, and in those with
obesity (PWVcf), hypertension (all PWV), or dyslipidemia
(PWVcf and PWVft); higher C-reactive protein (AIx, PWVcf,
and PWVft), reported smoking (PWV); and lower physical
activity levels (all measures) with a trend for higher sedentary
behavior (P=0.052 for PWVcf). Patterns were similar among
all measures of arterial stiffness and wave reflections (see
Tables S2 through S5 where differences were seen with 7, 14,
14, and 10 CVRFs for AIx, PWVcf, PWVft, and PWVcr,
respectively).
Generalized linear models exploring the association of the
burden of CVRFs over time on measures of arterial stiffness
and wave reflections are presented in Table 3. For each of the
CVRF AUCs, a model was adjusted for demographics, clinic
site, and duration of diabetes mellitus. Higher HbA1c AUC was
associated with adverse levels of all vascular parameters. A
measure of adiposity (either higher BMI and/or waist-to-
height ratio) or a measure of BP (higher SBP, diastolic BP,
and/or MAP) or lipids (lower HDL and/or higher non-HDL
cholesterol) was associated with higher stiffness and wave
reflections. Presence of CAN was significant for PWVcf only
after adjustments. The models in Table 3 were repeated with
the addition of adjustment for HbA1c AUC or log(IS) AUC (data
not shown). Adjusting for HbA1c resulted in no changes,
except non-HDL cholesterol was no longer statistically
significantly associated with PWVcr.
Full models including all CVRFs, adjusted for clinic site and
race, are presented in Table 4 (models with standardized beta
Table 2. Arterial Stiffness Overall and Stratified by Demographic and Clinical Characteristics at Follow-Up, Mean (SE)*
Covariate
AIx (%) PWVcf (m/s) PWVft (m/s) PWVcr (m/s)
Mean (SE) P Value Mean (SE) P Value Mean (SE) P Value Mean (SE) P Value
Overall 2.33 (0.28) 5.44 (0.03) 8.09 (0.03) 7.42 (0.03)
Age 0.007 <0.0001 <0.0001 <0.0001
Older (≥18) 3.08 (0.39) 5.87 (0.04) 8.54 (0.05) 7.67 (0.05)
Younger (<18) 1.60 (0.39) 5.06 (0.03) 7.69 (0.04) 7.19 (0.04)
Age at diagnosis <0.0001 <0.0001 <0.0001 <0.0001
Older (10–19) 3.49 (0.38) 5.80 (0.04) 8.42 (0.05) 7.57 (0.05)
Younger (<10) 1.09 (0.40) 5.08 (0.03) 7.77 (0.05) 7.27 (0.04)
Sex <0.0001 NS <0.0001 0.01
Female 0.47 (0.39) 5.44 (0.04) 7.89 (0.05) 7.34 (0.05)
Male 4.99 (0.37) 5.44 (0.04) 8.28 (0.05) 7.50 (0.04)
Race <0.0001 <0.0001 0.0003 <0.0001
Non-Hispanic white 3.01 (0.31) 5.37 (0.03) 8.07 (0.04) 7.33 (0.04)
Non-Hispanic black 0.97 (1.01) 5.72 (0.09) 8.45 (0.13) 8.12 (0.11)
Hispanic 0.33 (0.76) 5.58 (0.08) 7.86 (0.10) 7.36 (0.09)
Other 2.73 (1.38) 5.79 (0.23) 8.41 (0.23) 7.57 (0.16)
Glycated hemoglobin 0.0001 <0.0001 0.005 0.006
<9 3.35 (0.39) 5.33 (0.04) 8.00 (0.05) 7.33 (0.04)
≥9 1.22 (0.39) 5.56 (0.04) 8.19 (0.05) 7.51 (0.05)
Insulin sensitivity NS <0.0001 <0.0001 0.01
<8.15 (insulin resistant) 2.48 (0.32) 5.63 (0.03) 8.20 (0.04) 7.47 (0.04)
8.15+ (insulin sensitive) 2.07 (0.56) 4.96 (0.04) 7.81 (0.06) 7.29 (0.06)
Duration of diabetes mellitus NS <0.0001 <0.0001 0.002
<8 y 2.63 (0.39) 5.26 (0.03) 7.90 (0.05) 7.33 (0.05)
≥8 y 2.02 (0.39) 5.65 (0.04) 8.31 (0.05) 7.53 (0.04)
Cardiac autonomic neuropathy NS 0.0002 0.0005
No 2.75 (0.30) 5.45 (0.03) 8.08 (0.04) 7.42 (0.04) 0.09
Yes 2.68 (0.85) 5.76 (0.08) 8.46 (0.11) 7.60 (0.09)
AIx indicates augmentation index; NS, nonsignificant; PWVcf, pulse wave velocity, carotid-femoral; PWVcr, pulse wave velocity, carotid-radial; PWVft, pulse wave velocity, femoral-foot.
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estimates are found in Table S1). HbA1c AUC was statistically
significantly associated with all arterial measures, except
there was only a trend for PWVcr. There was a HbA1c AUC by
non-HDL interaction term that entered the model for AIx,
HbA1c by CAN for AIx and PWVft, and HbA1c by waist-to-height
ratio term for PWVcf. Duration of T1DM was positively
associated with higher stiffness or wave reflections. A
measure of adiposity (for all measures except PWVcr) and
MAP entered all the PWV models. Non-HDL cholesterol was
significantly associated with AIx and PWVcf. CAN was not
significant for any measure. Use of BP or lipid-lowering
medication, smoking, and sedentary behavior were not
significant, and being physically active was significantly
associated with PWVft and PWVcr (in a favorable direction).
Figure. Arterial stiffness means with standard error bars by glycosylated
hemoglobin (HbA1c levels, %) in youth and young adults with type 1 diabetes
mellitus. AIx indicates augmentation index; PWVcf, pulse wave velocity,
carotid-femoral; PWVcr, pulse wave velocity, carotid-radial; PWVft, pulse wave
velocity, femoral-foot.
Table 3. Association of Arterial Stiffness With AUC of Metabolic and Cardiovascular Risk Factors in Youth and Young Adults with
T1DM*
Cardiovascular Risk Factor
Included in the Model
AIx PWVcf PWVft PWVcr
Beta (SE) P Value Beta (SE) P Value Beta (SE) P Value Beta (SE) P Value
HbA1c (%) AUC 0.97 (0.20) <0.0001 0.07 (0.02) 0.0002 0.09 (0.03) 0.0002 0.08 (0.02) 0.0005
BMI z score AUC 0.05 (0.30) NS 0.23 (0.02) <0.0001 0.10 (0.04) 0.007 0.09 (0.03) 0.01
WHR AUC 24.95 (4.45) <0.0001 4.12 (0.39) <0.0001 0.38 (0.57) NS 0.15 (0.50) NS
SBP z score AUC 1.44 (0.32) <0.0001 0.13 (0.03) <0.0001 0.10 (0.04) 0.009 0.07 (0.04) 0.08
DBP z score AUC 1.40 (0.26) <0.0001 0.09 (0.02) 0.0003 0.07 (0.03) 0.02 0.11 (0.03) 0.0005
MAP (mm Hg) AUC 0.05 (0.04) NS 0.03 (0.00) <0.0001 0.03 (0.01) <0.0001 0.02 (0.00) 0.0006
HDL (mg/dL) AUC (10 mg/dL change) 0.03 (0.24) NS 0.05 (0.02) 0.02 0.01 (0.03) NS 0.02 (0.03) NS
Non-HDL AUC (10 mg/dL change) 0.47 (0.11) <0.0001 0.05 (0.01) <0.0001 0.01 (0.01) NS 0.03 (0.01) 0.02
CAN (yes vs no) 1.12 (0.82) NS 0.13 (0.07) 0.08 0.21 (0.10) 0.050 0.12 (0.10) NS
AIx indicates augmentation index; AUC, area under the curve; BMI, body mass index; CAN, cardiac autonomic neuropathy; DBP, diastolic blood pressure; HbA1c, glycated hemoblobin; HDL,
high-density lipoprotein; MAP, mean arterial pressure; NS, nonsignificant; PWVcf, pulse wave velocity, carotid-femoral; PWVcr, pulse wave velocity, carotid-radial; PWVft, pulse wave
velocity, femoral-foot; SBP, systolic blood pressure; T1DM, type 1 diabetes mellitus; WHR, waist-to-height ratio.
*Generalized linear models for each cardiovascular risk factor AUC adjusted for age at diagnosis, sex, race, clinic site, duration of diabetes mellitus, and 1 cardiovascular risk factor AUC.
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Removal from the model of variables that did not demonstrate
a statistically significant association did not change the R2
substantially but did result in a significant association of
HbA1c and non-HDL with PWVcr (data not shown).
Discussion
Our data demonstrate that in adolescents and young adults,
the duration of T1DM and glycemic control over time (HbA1c
AUC) are consistent determinants of association with arterial
stiffness and wave reflections regardless of sex and race and
after adjustment for other known CVRFs. However, increased
adiposity, higher BP, and adverse lipid levels were also
important correlates, suggesting that T1DM does affect the
vasculature but traditional CVRFs are also important. In our
previous work in a substudy of SEARCH (N=298), we also
found that CVRFs were important in predicting change in
PWVcf.11 These new data extend the observations to a larger
cohort with more racial and ethnic diversity that includes
additional arterial stiffness and wave reflection parameters
and examines the burden of risk factors over time (AUC).
Studies in adults have examined the relationship between
presence and control of T1DM and arterial stiffness and wave
reflections. One study of 89 adults (mean age, 34 years)
found that diabetes mellitus was an important determinant of
Aix, but the relationship was stronger in men and an
interaction with age suggested that duration of disease also
had an influence.26 In a smaller case-control study, AIx was
significantly higher in participants with T1DM as compared
with controls (7.11.6% versus 0.42.0%; P=0.01).27 They
also estimated PWV by calculating the time from the foot of
the aortic pressure wave to the inflection point and found this
higher in adults with diabetes mellitus.27 However, when PWV
was directly measured in another study, no significant
difference in PWV was seen between T1DM cases and
controls, although this study suffered from a small sample
size (N=17 with T1DM).28 Other investigators have found
higher PWV in participants with T1DM,29,30 consistent with
our previous work in the SEARCH study where we demon-
strated higher AIx and PWV in adolescents and young adults
(mean age, 17.8 years) with T1DM as compared with
controls,10 and presence of diabetes mellitus remained a
significant correlate even after adjusting for other CVRFs.31 In
the SEARCH CVD substudy, higher HbA1c was significantly
associated with change in only carotid-femoral PWV over
time.11 Our current study is able to demonstrate the effect of
burden of glycemic dyscontrol over time on a variety of
vascular parameters.
The relationship between duration of diabetes mellitus and
arterial stiffness and wave reflections has also been exam-
ined. Adults with T1DM for >10 years had higher PWV than
Table 4. Multivariable Associations of Metabolic and CVRFs with Arterial Stiffness in Youth and Young Adults With T1DM*
Parameter
AIx PWVcf PWVft PWVcr
Beta (SE) P Value Beta (SE) P Value Beta (SE) P Value Beta (SE) P Value
HbA1c (%) AUC 4.08 (1.04) 0.0004 0.32 (0.15) 0.03 0.01 (0.07) 0.94 0.05 (0.03) 0.08
Duration of T1DM, y 0.62 (0.16) <0.0001 0.10 (0.01) <0.0001 0.11 (0.02) <0.0001 0.06 (0.02) 0.003
Waist circumference AUC* 0.06 (0.03) 0.03
Waist-to-height ratio AUC 1.58 (0.66) 0.02
MAP (mm Hg) AUC 0.02 (0.00) <0.0001 0.03 (0.01) <0.0001 0.02 (0.01) 0.0002
Non-HDL AUC (10 mg/dL increase) 1.87 (0.67) 0.01 0.02 (0.01) 0.05 0.01 (0.01) NS 0.02 (0.01) 0.07
CAN: N (Y is ref) 13.36 (5.28) 0.01 0.13 (0.08) 0.09 1.13 (0.70) 0.11 0.08 (0.10) NS
Physically active: N (Y is ref) 0.48 (0.55) NS 0.05 (0.05) NS 0.15 (0.07) 0.04 0.15 (0.07) 0.03
HbA1c (%) AUC9Non-HDL AUC (10 mg/dL
increase)
0.19 (0.08) 0.01
HbA1c (%) AUC9CAN: N (Y is ref) 1.64 (0.60) 0.006 0.11 (0.08) 0.15
HbA1c (%) AUC9waist-to-height ratio AUC 0.75 (0.30) 0.01
Model R2 0.23 0.30 0.18 0.14
Reduced model R2 0.22 0.29 0.18 0.14
This reduced model excludes the variables that were not significant. AIx indicates augmentation index; AUC, area under the curve; CAN, cardiac autonomic neuropathy; HbA1c, glycated
hemoblobin; HDL, high-density lipoprotein; MAP, mean arterial pressure; PWVcf, pulse wave velocity, carotid-femoral; PWVcr, pulse wave velocity, carotid-radial; PWVft, pulse wave velocity,
femoral-foot; T1DM, type 1 diabetes mellitus.
*In generalized linear models, all variables listed, age, sex, race, use of blood pressure or lipid medication, smoking, sedentary behavior, and clinic site were included simultaneously. For
AIx, model was adjusted for height at the time of the measure and waist AUC, other outcomes use the National Health and Nutrition Examination Survey waist-to-height ratio AUC.
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those with shorter exposure to disease, with duration and SBP
remaining important determinants in multivariable analyses.32
In a small study of 30 children with T1DM, PWV correlated
with duration of diabetes mellitus, but AIx did not.33 Our
previous study (N=535) found a relationship between duration
and both AIx and PWV.34
The effect of metabolic control and arterial stiffness and
wave reflections is complex. Although induction of acute
hyperglycemia was found to increase both PWV and AIx in
adults with T1DM,35 no relationship was found between
chronic glycemic control (HbA1c) and AIx in a study that
included only adult women.36 When we looked at glycemic
control in younger adolescents (mean age, 14.6 years) of
both sexes with T1DM, we also found that although HbA1c
correlates with arterial stiffness and wave reflections, it was
not a significant determinant of AIx or PWV once adjusted for
BP and lipids.34 Similarly, in children with T1DM, no relation-
ship was seen between HbA1c and ultrasound-based abdom-
inal aortic distensibility, a measure that correlates with
PWV.37 However, in a study using magnetic resonance
imaging, perhaps a more precise measure than ultrasound,
an inverse relationship was found between HbA1c and aortic
distensibility in adolescents with T1DM.38 Furthermore in a
previous smaller substudy of the SEARCH study, we examined
298 adolescents with T1DM from 2 of the SEARCH sites who
had CVRFs and PWV at baseline (mean age, 14.5 years) and
after 5 years of follow up. A lower insulin sensitivity score,
which contains HbA1c in the calculation, was associated with
a greater rate of change in PWV over 5 years.11 These
observations along with our current work suggest that there is
a relationship between glycemic control and arterial stiffness,
but the effect is modest, requiring a larger sample size or
longer duration of follow-up to detect.
In adults, adiposity and BP have been found to be
important predictors of arterial parameters.31,39 Pediatric
studies also show a direct relationship between greater AIx
and higher BMI,40 and higher PWV and higher lipid and BP
levels.41 Previous SEARCH analyses confirm these relation-
ships, demonstrating that adiposity, BP, and lipids are
determinants of higher arterial stiffness in cross-sectional
analyses31,42 and contribute to increasing arterial stiffness
over time.11 Our current work extends these observations by
demonstrating the effect of burden of risk factors over time
(using AUC) on arterial stiffness in young adults with T1DM.
There are numerous mechanisms by which poor metabolic
control may affect vascular parameters. Animal models have
shown that in the setting of insulin resistance, there is
reduced activation of the nitric oxide signaling pathway
(vasodilating) and enhanced activation of the endothelin
pathway (vasoconstricting), resulting in increased vascular
tone.43 Because nitric oxide attenuates production of proin-
flammatory cytokines, insulin resistance also leads to an
inflammatory milieu and increased reactive oxygen species,
which also contribute to vascular dysfunction.44 Hyper-
glycemia also leads to formation of advanced glycation end
products, which may result in abnormal cross-linking of
collagen and elastin fibers.45 These advanced glycation end
products were independently associated with PWV in adults
with T1DM.46 Diabetes mellitus is also associated with
development of CAN47 with concomitant sympathetic pre-
dominance, resulting in increased arterial stiffness in adults
with T1DM.48–50 SEARCH investigators have demonstrated a
similar relationship in youth with T1DM between reduced
heart rate variability, reflecting CAN, and increased arterial
stiffness.9 Our data suggest that the burden of CAN over time
has only a modest effect on arterial stiffness when other
CVRFs are taken into account.
Limitations
Our study examines the effect of CVRF burden on arterial
parameters in young individuals with T1DM. Therefore, our
findings may not be generalizable to healthy youth or those
with other high-risk conditions such as uncomplicated
obesity, type 2 diabetes mellitus, hypertension, dyslipidemia,
or chronic kidney disease. We were also unable to compare
the effect of CVRFs on arterial parameters in people without
diabetes mellitus because of constraints of the overall design
of the parent SEARCH study, but case-control comparisons
were thoroughly explored in our ancillary SEARCH CVD
study.31 Although we have CVRF data over time, we collected
only arterial parameters measures at follow-up, so we can
only demonstrate association and cannot conclude that the
risk factors caused any vascular dysfunction.
There are many controversies in the measurement of
arterial parameters. The usefulness of AIx, a measure of wave
reflection, to evaluate arterial health has been challenged51
because it may be affected by factors such as anatomy or
peripheral vascular resistance, not directly related to arterial
stiffness. Furthermore, the contribution of the forward and
backward waves may be different,52 and we were not able to
assess these features in the current study. However, a large
meta-analysis in adults demonstrated that higher AIx was
associated with greater incidence of cardiovascular events53;
therefore, we believe our examination of AIx in a young
diabetic population adds to the literature. The relevance of the
peripheral stiffness measures is not entirely clear, as no
studies have evaluated the relationship between PWVcr or
PWVft and cardiovascular events. These measures may be
more sensitive to vascular tone. However, we include these
measures because few studies have evaluated the relation-
ship between arterial stiffness and peripheral artery dis-
ease,54 but limited studies in adults with diabetes mellitus
suggest a relationship between PWV in the leg and presence
DOI: 10.1161/JAHA.118.010150 Journal of the American Heart Association 8
Burden of CVRF and Arterial Stiffness in T1DM Urbina et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on A
pril 2, 2020
of peripheral artery disease,55 and one group has found higher
PWVcr in women with insulin resistance56 and offspring of
adults with diabetes mellitus,57 so there may be utility in
measuring PWV in the arm in diabetes mellitus. We also used
the “subtraction” rather than “80% direct” method to measure
arterial path length purported to be more accurate compared
with magnetic resonance imaging.58 However, another larger
study suggested the subtraction method is more accurate
compared with magnetic resonance imaging.59
Conclusion
The major factors associated with wave reflections (AIx) and
arterial stiffness (PWV) in young people with T1DM are
duration of diabetes mellitus, glycemic control over time, and
traditional CVRFs including obesity, BP, and lipids. Because
presence of greater numbers of ideal cardiovascular health
metrics in youth with T1DM is associated with lower arterial
stiffness,42 efforts to improve glycemic control combined with
interventions to lower CVRFs may prevent future cardiovas-
cular events in young individuals with T1DM.
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Table S1. Multivariable Associations of Metabolic and CVRFs with Arterial Stiffness in Youth and 
Young Adults with T1D (standardized beta estimates).* 
 
Parameter† AIx PWVcf PWVft PWVcr 
Intercept 56.00 (5.95) <.0001 5.76 (0.18) <.0001 8.22 (0.25) <.0001 7.69 (0.24) <.0001 
HbA1c (%) AUC 0.81 (0.30) 0.0072 0.06 (0.03) 0.0188 0.12 (0.04) 0.0017 0.11 (0.05) 0.0159 
Duration of T1D (yrs) 1.19 (0.30) <.0001 0.20 (0.03) <.0001 0.21 (0.04) <.0001 0.07 (0.04) 0.0756 
Age at diagnosis (yrs) 0.45 (0.42) 0.2861 0.31 (0.03) <.0001 0.27 (0.05) <.0001 0.11 (0.04) 0.0031 
Female 0.52 (0.33) 0.1135 -0.02 (0.03) 0.3539 -0.14 (0.04) 0.0003 -0.09 (0.04) 0.0150 
Height (m) -40.28 (3.48) <.0001       
Waist circumference AUC 0.06 (0.03) 0.0304       
Waist to Height ratio 
AUC 
  0.21 (0.03) <.0001 -0.10 (0.04) 0.0173 -0.05 (0.04) 0.1765 
MAP (mmHg) AUC 0.37 (0.36) 0.2952 0.16 (0.03) <.0001 0.24 (0.05) <.0001 0.16 (0.04) 0.0002 
On BP med 0.22 (0.27) 0.4227 0.01 (0.03) 0.7820 0.02 (0.04) 0.5303 -0.02 (0.03) 0.5458 
Non-HDL AUC (10 mg/dl 
increase) 
0.77 (0.30) 0.0114 0.05 (0.03) 0.0469 0.02 (0.04) 0.5896 0.06 (0.04) 0.0744 
CAN 0.20 (0.28) 0.4599 0.04 (0.03) 0.0930 0.06 (0.04) 0.1201 0.03 (0.03) 0.4541 
On Lipid med -0.14 (0.25) 0.5781 -0.01 (0.02) 0.6038 -0.04 (0.03) 0.3063 -0.02 (0.03) 0.5781 
Smoking (Never is ref)         
    Current 0.12 (0.30) 0.6742 -0.01 (0.03) 0.7362 0.03 (0.04) 0.4639 0.01 (0.04) 0.7639 
    Former -0.30 (0.29) 0.3125 -0.00 (0.03) 0.9972 0.03 (0.04) 0.4641 -0.01 (0.04) 0.7823 
Physically Active -0.24 (0.27) 0.3878 -0.02 (0.03) 0.3475 -0.07 (0.04) 0.0449 -0.07 (0.03) 0.0328 
Sedentary -0.05 (0.28) 0.8682 0.02 (0.03) 0.3296 -0.03 (0.04) 0.4903 -0.03 (0.03) 0.3446 
HbA1c (%) AUC x Non-
HDL AUC (10 mg/dl 
increase) 
-0.66 (0.27) 0.0140     
  
HbA1c (%) AUC x CAN: 
N(Y is ref) 
0.72 (0.26) 0.0061       
HbA1c (%) AUC x Waist 
to Height ratio AUC 
  0.06 (0.02) 0.0110 -0.05 (0.03) 0.1536   
Model R2 0.23 0.30 0.18 0.14 
Reduced model R2 0.22 0.29 0.18 0.14 
 
*In generalized linear models, all variables listed, race and clinic site were included simultaneously.  For AIx, model 
was adjusted for height at the time of the measure and waist AUC, other outcomes use NHANES waist to height 
ratio area under the curve (AUC).  AIx = augmentation index; PWVcf = pulse wave velocity, carotid-
femoral; PWVft = pulse wave velocity, femoral-foot, PWVcr = pulse wave velocity, carotid-radial. 
Reduced model excludes the variables that in the tables have a p-value labeled as NS.  †HbA1c = glycated 
hemoblobin, T1D = type 1 diabetes, MAP = mean arterial pressure, BP med = blood pressure lowering medication, 
CAN = cardiac autonomic neuropathy, lipid med = lipid lowering medication. 
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Table S2. Generalized Linear Multivariable Models of Associations of Metabolic and CVRFs with 
Augmentation Index in Youth and Young Adults with T1D.* 
Parameter† 
Min. Adjusted *Full Model **Reduced Model 
beta (se) p-value beta (se) p-value beta (se) p-value 
HbA1c (%) AUC 0.97 (0.20) <.0001 4.08 (1.04) <.0001 3.97 (1.02) 0.0001 
Waist circumference AUC 0.01 (0.03) 0.72 0.06 (0.03) 0.03 0.11 (0.02) <.0001 
BMI z-score AUC 0.05 (0.30) 0.88     
Non-HDL AUC (10 mg/dl 
increase) 
0.47 (0.11) <.0001 1.87 (0.67) 0.005 1.86 (0.66) 0.005 
HDL AUC (10 mg/dl increase) -0.03 (0.24) 0.90     
SBP z-score AUC 1.44 (0.32) <.0001     
DBP z-score AUC 1.40 (0.26) <.0001     
MAP AUC 0.05 (0.04) 0.29 0.05 (0.05) 0.30   
CAN: No (Yes is ref) -1.12 (0.82) 0.17 13.36 (5.28) 0.01 11.98 (5.17) 0.02 
Physically Active: No (Yes is 
ref) 
1.26 (0.54) 0.02 0.48 (0.55) 0.39   
HbA1c (%) AUC x Non-HDL 
AUC (10 mg/dl increase) 
-0.17 (0.08) 0.02 -0.19 (0.08) 0.01 -0.18 (0.07) 0.01 
HbA1c (%) AUC x CAN -1.57 (0.57) 0.006 -1.64 (0.60) 0.006 -1.50 (0.59) 0.01 
Model R2  0.23 0.22 
Variables included in the minimally adjusted models are the variable of interest, age at diagnosis, duration of diabetes, sex, 
race, and clinical site.  When testing interactions, the main effects were also included in the model (not presented). 
*The full model includes variables with results, age at diagnosis, duration of diabetes, sex, race, use of BP or lipid 
medication, smoking, sedentary behavior, height, and clinic site.   
**This reduced model includes variables used in the full model that were significant and main effects of interactions.  
Variables included in the model that are not in the table include duration of diabetes, race, height, and clinic site. 
†HbA1c = glycated hemoglobin, MAP = mean arterial pressure, BP med = blood pressure lowering medication, CAN = 
cardiac autonomic neuropathy, lipid med = lipid lowering medication. 
 
Interaction interpretation for Aix: When both HbA1c & non-HDL AUC, there is lower effect on AIx. 
 
HbA1c AUC level 
5 7 9 11 
Change in Aix when non-HDL 
AUC is increased by 10 mg/dl 
0.96 0.60 0.24 -0.12 
 
When both HbA1c increases and CAN is present there is greater increase in AIx 
 
 Non-HDL AUC level 
CAN status 60 90 120 150 
Change in Aix when HbA1c 
AUC increases by one unit 
No 1.35 0.80 0.25 -0.30 
Yes 2.85 2.30 1.75 1.20 
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Table S3. Generalized Linear Multivariable Models of Associations of Metabolic and CVRFs with 
Carotid-Femoral Pulse Wave Velocity in Youth and Young Adults with T1D.* 
Parameter† 
Min. Adjusted *Full Model **Reduced Model 
beta (se) p-value beta (se) p-value beta (se) p-value 
HbA1c (%) AUC 0.07 (0.02) 0.0001 -0.32 (0.15) 0.03 -0.30 (0.14) 0.04 
Waist to Height ratio AUC (0.1 
increase) 
0.41 (0.04) <.0001 -0.30 (0.25) 0.23 -0.27 (0.25) 0.28 
BMI z-score AUC 0.23 (0.03) <.0001     
Non-HDL AUC (10 mg/dl 
increase) 
0.05 (0.01) <.0001 0.02 (0.01) 0.05 0.02 (0.01) 0.04 
HDL AUC (10 mg/dl increase) -0.05 (0.02) 0.02     
SBP z-score AUC 0.13 (0.03) <.0001     
DBP z-score AUC 0.09 (0.02) 0.0003     
MAP AUC 0.03 (0.00) <.0001 0.02 (0.00) <.0001 0.02 (0.00) <.0001 
CAN: No (Yes is ref) -0.13 (0.07) 0.08 -0.13 (0.08) 0.09 -0.14 (0.08) 0.07 
Physically Active: No (Yes is 
ref) 
0.07 (0.05) 0.14 0.05 (0.05) 0.35   
HbA1c (%) AUC x Waist to 
Height ratio AUC 
0.50 (0.25) 0.05 0.75 (0.30) 0.01 0.07 (0.03) 0.02 
Model R2  0.30 0.29 
Variables included in the minimally adjusted models are the variable of interest, age at diagnosis, duration of diabetes, 
sex, race, and clinical site.  When testing interactions, the main effects were also included in the model (not presented). 
*The full model includes variables with results, age at diagnosis, duration of diabetes, sex, race, use of BP or lipid 
medication, smoking, sedentary behavior, and clinic site.   
**This reduced model includes variables used in the full model that were significant and main effects of interactions.  
Variables included in the model that are not in the table include age at diagnosis, duration of diabetes, race, and clinic site 
†HbA1c = glycated hemoglobin, MAP = mean arterial pressure, BP med = blood pressure lowering medication, CAN = 
cardiac autonomic neuropathy, lipid med = lipid lowering medication. 
 
Interaction interpretation: 
As HbA1c AUC and waist to height ratio AUC increase the effect they have on PWVcf increases.   
 HbA1c AUC level 
5 7 9 11 
Change in PWVcf when increasing 
waist to height ratio AUC by 0.1 
0.08 0.22 0.36 0.50 
 
This table shows the effect on PWVcf by a one unit change in HbA1c AUC when waist to height ratio 
AUC is held constant at the different values. 
 Waist to Height ratio AUC level 
0.4 0.5 0.6 0.7 
Change in PWVcf when increasing 
HbA1c AUC by one 
-0.02 0.05 0.13 0.20 
  
D
ow
nloaded from
 http://ahajournals.org by on A
pril 2, 2020
Table S4. Generalized Linear Multivariable Models of Associations of Metabolic and CVRFs with 
Femoral-Foot Pulse Wave Velocity in Youth and Young Adults with T1D.* 
Parameter† 
Min. Adjusted *Full Model **Reduced Model 
beta (se) p-value beta (se) p-value beta (se) p-value 
HbA1c (%) AUC 0.09 (0.03) 0.0002 -0.01 (0.07) 0.94 0.09 (0.03) 0.0003 
Waist to Height ratio AUC (0.1 
increase) 
-0.04 (0.06) 0.51 -0.16 (0.07) 0.02 -0.15 (0.06) 0.0140 
BMI z-score AUC -0.10 (0.04) 0.007     
Non-HDL AUC (10 mg/dl 
increase) 
0.01 (0.01) 0.37 0.01 (0.01) 0.59   
HDL AUC (10 mg/dl increase) -0.01 (0.03) 0.69     
SBP z-score AUC 0.10 (0.04) 0.009     
DBP z-score AUC 0.07 (0.03) 0.02     
MAP AUC 0.03 (0.01) <.0001 0.03 (0.01) <.0001 0.03 (0.01) <.0001 
CAN: No (Yes is ref) -0.21 (0.10) 0.05 -1.13 (0.70) 0.11 -0.14 (0.11) 0.1861 
Physically Active: No (Yes is 
ref) 
0.17 (0.07) 0.01 0.15 (0.07) 0.04 0.17 (0.07) 0.0119 
HbA1c (%) AUC x CAN 0.16 (0.07) 0.03 0.11 (0.08) 0.15   
Model R2  0.18 0.18 
 
Variables included in the minimally adjusted models are the variable of interest, age at diagnosis, duration of diabetes, 
sex, race, and clinical site.  When testing interactions, the main effects were also included in the model (not presented). 
*The full model includes variables with results, age at diagnosis, duration of diabetes, sex, race, use of BP or lipid 
medication, smoking, sedentary behavior, and clinic site. 
**This reduced model includes variables used in the full model that were significant and main effects of interactions.  
Variables included in the model that are not in the table include age at diagnosis, duration of diabetes, sex, race, and 
clinic site. 
†HbA1c = glycated hemoglobin, MAP = mean arterial pressure, BP med = blood pressure lowering medication, CAN = 
cardiac autonomic neuropathy, lipid med = lipid lowering medication. 
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Table S5. Generalized Linear Multivariable Models of Associations of Metabolic and CVRFs with 
Carotid-Radial Pulse Wave Velocity in Youth and Young Adults with T1D.* 
Parameter† 
Min. Adjusted *Full Model **Reduced Model 
beta (se) p-value beta (se) p-value beta (se) p-value 
HbA1c (%) AUC 0.08 (0.02) 0.0005 0.05 (0.03) 0.08 0.06 (0.03) 0.03 
Waist to Height ratio AUC (0.1 
increase) 
-0.02 (0.05) 0.76 -0.08 (0.06) 0.18   
BMI z-score AUC -0.09 (0.03) 0.01     
Non-HDL AUC (10 mg/dl 
increase) 
0.03 (0.01) 0.02 0.02 (0.01) 0.07 0.02 (0.01) 0.22 
HDL AUC (10 mg/dl increase) 0.02 (0.03) 0.48     
SBP z-score AUC 0.07 (0.04) 0.08     
DBP z-score AUC 0.11 (0.03) 0.0005     
MAP AUC 0.02 (0.00) 0.0006 0.02 (0.01) 0.0002 0.01 (0.01) 0.007 
CAN: No (Yes is ref) -0.12 (0.10) 0.24 -0.08 (0.10) 0.45   
Physically Active: No (Yes is 
ref) 
0.15 (0.06) 0.02 0.15 (0.07) 0.03 0.14 (0.07) 0.04 
Model R2  0.14 0.13 
 
Variables included in the minimally adjusted models are the variable of interest, age at diagnosis, duration of diabetes, 
sex, race, and clinical site.  When testing interactions, the main effects were also included in the model (not presented). 
*The full model includes variables with results, age at diagnosis, duration of diabetes, sex, race, use of BP or lipid 
medication, smoking, sedentary behavior, and clinic site. 
**This reduced model includes variables used in the full model that were significant and main effects of interactions.  
Variables included in the model that are not in the table include age at diagnosis, duration of diabetes, sex, race, and 
clinic site. 
†HbA1c = glycated hemoglobin, MAP = mean arterial pressure, BP med = blood pressure lowering medication, CAN = 
cardiac autonomic neuropathy, lipid med = lipid lowering medication. 
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Figure S1. Arterial Stiffness means with standard error bars by glycosylated hemoglobin (HbA1c 
levels, %) in Youth and Young Adults with Type 1 Diabetes adjusted (for mean arterial pressure, 
age, and sex).   
 
 
 
AIx = augmentation index; PWVcf = pulse wave velocity, carotid-femoral; PWVft = pulse wave velocity, 
femoral-foot, PWVcr = pulse wave velocity, carotid-radial. 
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